Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H5O3.C5H14NO |
Molecular Weight | 241.2836 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
InChI
InChIKey=UDKCHVLMFQVBAA-UHFFFAOYSA-M
InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1
Molecular Formula | C7H6O3 |
Molecular Weight | 138.1207 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C5H13NO |
Molecular Weight | 103.1628 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdfCurator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html
Sources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html
Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.
Originator
Sources: http://www.casinapioiv.va/content/dam/accademia/pdf/acta18/acta18-szczeklik.pdfhttps://books.google.ru/books?id=iUpwBAAAQBAJ&pg=PT83&lpg=PT83&dq=Methyl+salicylate+Auguste+Andr%C3%A9+Thomas+Cahours&source=bl&ots=nFDf2n2bpT&sig=wAKTDamdc7xWWgRxOrTeokeji8g&hl=ru&sa=X&ved=0ahUKEwj-q8769PzTAhVFfhoKHYEqDgkQ6AEIODAD#v=onepage&q=Methyl%20salicylate%20Auguste%20Andr%C3%A9%20Thomas%20Cahours&f=false
Curator's Comment: first isolated in 1843
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: http://www.drugbank.ca/drugs/DB00936 |
|||
Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00936 |
|||
Target ID: CHEMBL2311236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26101955 |
1.48 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date2008 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date2012 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date2012 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date2012 |
Doses
Dose | Population | Adverse events |
---|---|---|
30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
Other AEs: Redness, Scales... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Redness | 30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
|
Scales | 30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/9207195/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
major | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of salicylates on evoked otoacoustic emissions and remote masking in humans. | 1999 May-Jun |
|
Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. | 1999 Sep |
|
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats. | 2001 |
|
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries. | 2001 |
|
The solvent shells of cluster ions produced by direct electric field extraction from glycerol/water mixtures. | 2001 |
|
Arabidopsis genome sequence as a tool for functional genomics in tomato. | 2001 |
|
Unraveling regulatory networks in plant defense using microarrays. | 2001 |
|
Abnormal callose response phenotype and hypersusceptibility to Peronospoara parasitica in defence-compromised arabidopsis nim1-1 and salicylate hydroxylase-expressing plants. | 2001 Apr |
|
Nitric oxide: comparative synthesis and signaling in animal and plant cells. | 2001 Apr |
|
Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. | 2001 Apr |
|
Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart. | 2001 Apr 30 |
|
Non-ionic micellar affinity capillary electrophoresis for analysis of interactions between micelles and drugs. | 2001 Feb |
|
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay. | 2001 Feb |
|
A hot pepper cDNA encoding a pathogenesis-related protein 4 is induced during the resistance response to tobacco mosaic virus. | 2001 Feb 28 |
|
Non-uniform mapping of stress-induced, motility-related charge movement in the outer hair cell plasma membrane. | 2001 Jan |
|
Increases in the mutation frequency at which fusidic acid-resistant Staphylococcus aureus arise with salicylate. | 2001 Jan |
|
Guidelines for the management of cutaneous warts. | 2001 Jan |
|
Ion channel-forming alamethicin is a potent elicitor of volatile biosynthesis and tendril coiling. Cross talk between jasmonate and salicylate signaling in lima bean. | 2001 Jan |
|
The possibility of achieving an interactive mixture with high dose homogeneity containing an extremely low proportion of a micronised drug. | 2001 Jan |
|
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism. | 2001 Jan 15 |
|
Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray powder diffraction data. | 2001 Jan 16 |
|
Synthesis and metal binding properties of salicylate-, catecholate-, and hydroxypyridinonate-functionalized dendrimers. | 2001 Jan 5 |
|
Release of salicylic acid, diclofenac acid and diclofenac acid salts from isotropic and anisotropic nonionic surfactant systems across rat skin. | 2001 Jan 5 |
|
Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells. | 2001 Jan-Feb |
|
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus. | 2001 Jul 6 |
|
Development of QSARs to investigate the bacterial toxicity and biotransformation potential of aromatic heterocylic compounds. | 2001 Mar |
|
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs. | 2001 Mar |
|
Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. | 2001 May |
|
Acanthoamoeba attachment to contact lenses. | 2001 May |
|
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein. | 2001 May |
|
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum. | 2001 May 8 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/salicylic-acid.html
The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1811921
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:02:46 GMT 2023
by
admin
on
Fri Dec 15 15:02:46 GMT 2023
|
Record UNII |
KD510K1IQW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02BA03
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
||
|
WHO-VATC |
QN02BA03
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000092173
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
SUB06219MIG
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
DB14006
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
2016-36-6
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
217-948-8
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
DTXSID8062103
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
C76798
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
m3483
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2104095
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
54686350
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
KD510K1IQW
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
20974
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | RxNorm | ||
|
1938
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
C015075
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY | |||
|
KD510K1IQW
Created by
admin on Fri Dec 15 15:02:46 GMT 2023 , Edited by admin on Fri Dec 15 15:02:46 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |